Original Study| Volume 22, ISSUE 3, P606.e7-606.e18, March 2021

Download started.


Combined Effects of Frailty and Polypharmacy on Health Outcomes in Older Adults: Frailty Outweighs Polypharmacy

Published:August 29, 2020DOI:



      Existing studies cannot evaluate the time-varying properties of frailty and polypharmacy despite raising concerns about their combined effects in older individuals.
      This study investigated the longitudinal association between different combined statuses of frailty and polypharmacy on risks of adverse outcomes.


      Retrospective cohort study.

      Setting and Participants

      Subjects aged between 65 and 100 years (n = 100,000) were identified from Taiwan's National Health Insurance Research Database.


      Frailty was categorized into fit, mild, moderate, and severe frailty based on the multimorbidity frailty index. Concomitant use of 5 to 9 and ≥10 chronic medications was considered polypharmacy and excessive polypharmacy. We used generalized estimating equation models to examine the association among 12 groups of combined effects of frailty and polypharmacy and risks of all-cause mortality, all-cause hospitalization, and unplanned hospitalization. Age-stratified analyses were conducted for those aged 65 to 74, 75 to 84, and 85+ years.


      Compared with fit without polypharmacy, severe frailty with excess polypharmacy was associated with increased risks of adverse outcomes, particularly unplanned hospitalization (adjusted relative risk (aRR): 20.01 [95% confidence interval (CI)] 19.30–20.75). However, the combined effects varied in distinct groups. Within each polypharmacy category, there were dose-response associations between frailty category and adverse outcomes. For instance, within the polypharmacy group, the aRRs of mortality were 1.58 (1.52–1.64), 2.70 (2.60–2.80), 4.62 (4.44–4.82), and 6.81 (6.50–7.13) for the fit and mild, moderate, and severe frailty groups, respectively. By contrast, within each frailty category, the dose-response association between polypharmacy and adverse outcomes was limited to fit and mildly frail people. Age-stratified analyses yielded similar results.

      Conclusions and Relevance

      Both frailty and polypharmacy modified the risks of mortality and hospital admissions in older people, but the combined effects varied in distinct groups. This study thus highlights the potential to optimize care of older people by capturing the dynamic and combined changes related to frailty and polypharmacy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Clegg A.
        • Young J.
        • Iliffe S.
        • et al.
        Frailty in elderly people.
        Lancet (London, England). 2013; 381: 752-762
        • Fried L.P.
        • Tangen C.M.
        • Walston J.
        • et al.
        Frailty in older adults: Evidence for a phenotype.
        J Gerontol A Biol Sci Med Sci. 2001; 56: M146-M156
        • Rockwood K.
        • Mitnitski A.
        Frailty in relation to the accumulation of deficits.
        J Gerontol A Biol Sci Med Sci. 2007; 62: 722-727
        • Vermeiren S.
        • Vella-Azzopardi R.
        • Beckwee D.
        • et al.
        Frailty and the prediction of negative health outcomes: A meta-analysis.
        J Am Med Dir Assoc. 2016; 17: 1163.e1-1163.e17
        • Romero Rizos L.
        • Abizanda Soler P.
        [Frailty as a predictor of adverse events in epidemiological studies: Literature review].
        Revista espanola de geriatria y gerontologia. 2013; 48: 285-289
        • Wen Y.C.
        • Chen L.K.
        • Hsiao F.Y.
        Predicting mortality and hospitalization of older adults by the multimorbidity frailty index.
        PLoS One. 2017; 12: e0187825
        • Chiu M.H.
        • Lee H.D.
        • Hwang H.F.
        • et al.
        Medication use and fall-risk assessment for falls in an acute care hospital.
        Geriatr Gerontol Int. 2015; 15: 856-863
        • Hein C.
        • Forgues A.
        • Piau A.
        • et al.
        Impact of polypharmacy on occurrence of delirium in elderly emergency patients.
        J Am Med Dir Assoc. 2014; 15: 850.e11-850.e15
        • Maher R.L.
        • Hanlon J.
        • Hajjar E.R.
        Clinical consequences of polypharmacy in elderly.
        Exp Opin Drug Saf. 2014; 13: 57-65
        • Lu W.H.
        • Wen Y.W.
        • Chen L.K.
        • Hsiao F.Y.
        Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: A retrospective cohort study.
        CMAJ. 2015; 187: E130-E137
        • Herr M.
        • Robine J.M.
        • Pinot J.
        • et al.
        Polypharmacy and frailty: Prevalence, relationship, and impact on mortality in a French sample of 2350 old people.
        Pharmacoepidemiol Drug Saf. 2015; 24: 637-646
        • Bennett A.
        • Gnjidic D.
        • Gillett M.
        • et al.
        Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: A prospective cohort study.
        Drugs Aging. 2014; 31: 225-232
        • Saum K.U.
        • Schottker B.
        • Meid A.D.
        • et al.
        Is polypharmacy associated with frailty in older people? Results from the ESTHER Cohort Study.
        J Am Geriatr Soc. 2017; 65: e27-e32
        • Veronese N.
        • Stubbs B.
        • Noale M.
        • et al.
        Polypharmacy is associated with higher frailty risk in older people: An 8-year longitudinal cohort study.
        J Am Med Dir Assoc. 2017; 18: 624-628
        • Bonaga B.
        • Sanchez-Jurado P.M.
        • Martinez-Reig M.
        • et al.
        Frailty, polypharmacy, and health outcomes in older adults: The Frailty and Dependence in Albacete Study.
        J Am Med Dir Assoc. 2018; 19: 46-52
        • Poudel A.
        • Peel N.M.
        • Nissen L.M.
        • et al.
        Adverse outcomes in relation to polypharmacy in robust and frail older hospital patients.
        J Am Med Dir Assoc. 2016; 17: 767.e9-767.e13
        • Rosted E.
        • Schultz M.
        • Sanders S.
        Frailty and polypharmacy in elderly patients are associated with a high readmission risk.
        Dan Med J. 2016; 63: A5274
        • Travers J.
        • Romero-Ortuno R.
        • Bailey J.
        • Cooney M.T.
        Delaying and reversing frailty: A systematic review of primary care interventions.
        Br J Gen Pract. 2019; 69: e61-e69
        • Hsiao F.-Y.
        • Yang C.-L.
        • Huang Y.-T.
        • et al.
        Using Taiwan’s national health insurance research databases for pharmacoepidemiology research.
        J Food Drug Anal. 2007; 15: 99-108
        • WHO Collaborating Centre for Drug Statistics Methodology
        ATC/DDD index 2019.
        (Available at:)
        Date accessed: July 1, 2019
        • Lin C.W.
        • Wen Y.W.
        • Chen L.K.
        • Hsiao F.Y.
        Potentially high-risk medication categories and unplanned hospitalizations: A case-time-control study.
        Sci Rep. 2017; 7: 41035
        • Lin M.H.
        • Yang A.C.
        • Wen T.H.
        Using regional differences and demographic characteristics to evaluate the principles of estimation of the residence of the population in National Health Insurance Research Databases (NHIRD).
        Taiwan J Public Health. 2011; 30: 347-360
        • Lee H.Y.
        • Huang H.T.
        • Hsu Y.H.
        • Lin W.
        Change in the cross-boundary flow of emergent care in Taiwan, 2001–2010.
        Taiwan J Public Health. 2014; 33: 64-74
        • Liu C.Y.
        • Hung Y.T.
        • Chuang Y.L.
        • et al.
        Incorporating Development stratification of Taiwan townships into sampling design of large scale health interview survey.
        J Health Manag. 2006; 4: 1-22
        • Zeger S.L.
        • Liang K.Y.
        • Albert P.S.
        Models for longitudinal data: A generalized estimating equation approach.
        Biometrics. 1988; 44: 1049-1060
        • Lindquist K.
        How can I estimate relative risk in SAS using proc genmod for common outcomes in cohort studies.
        (Available at:)
        • Chamberlain A.M.
        • Finney Rutten L.J.
        • Manemann S.M.
        • et al.
        Frailty trajectories in an elderly population-based cohort.
        J Am Geriatr Soc. 2016; 64: 285-292
        • Tarazona-Santabalbina F.J.
        • Gomez-Cabrera M.C.
        • Perez-Ros P.
        • et al.
        A multicomponent exercise intervention that reverses frailty and improves cognition, emotion, and social networking in the community-dwelling frail elderly: A randomized clinical trial.
        J Am Med Dir Assoc. 2016; 17: 426-433